Press Releases in 2008

Check out the latest press releases from Novus. For direct media requests, contact us at novus@novusbio.com.
View Press Releases From: 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007

New Lightning-Link Conjugate & Conjugate Pairs Available from Novus Biologicals & Innova Biosciences

Release Date: 
Wednesday, December 17, 2008 - 07:00

The Lightning Link kits now come in a huge array of available labels for all of your antibody labelling needs. In addition to the standards such as HRP, AP, Biotin, Fluroescein, and PE, you can now conjugate your single vials of antibody with the full range of Cy Dyes and Atto Dyes. Atto Dyes come in 10 different wavelengths for complicated signal reporting. Tandem conjugation is also possible now with Cy5.5/PE and Cy5.5/PerCP kits available. More kits are being released on a regular basis.

Mainsail Partners Invests in Novus Biologicals

Release Date: 
Friday, November 21, 2008 - 07:00

SAN FRANCISCO, CA – Mainsail Partners, a San Francisco based private equity firm, announced today that it has completed an equity investment in Novus Biologicals, a leading provider of antibodies, peptides, proteins and other reagents for life science research, based in Littleton, CO. Financial details of the transaction have not been released.

Beclin Antibody Sample Pack and SuperNovus Pack now available from Novus Biologicals

Release Date: 
Tuesday, November 11, 2008 - 07:00

Beclin 1 is the first identified mammalian gene to mediate autophagy and also has tumor suppressor and antiviral function. Autophagy, a process of bulk protein degradation through an autophagosomic-lysosomal pathway, is important for differentiation, survival during nutrient deprivation, and normal growth control, and is often defective in tumor cells.

Novus Biologicals, Inc Ranked Number 22nd in Deloitte's Technology Fast 50 Program for Colorado.

Release Date: 
Tuesday, October 28, 2008 - 06:00

Littleton, CO, October 24, 2008 — Novus Biologicals, Inc. has been named to Deloitte's prestigious Technology Fast 50 Program for Colorado, a ranking of the 50 fastest growing technology, media, telecommunications, and life sciences companies in the area by Deloitte LLP, one of the nation’s leading professional services organizations. Rankings are based on the percentage revenue growth over five years from 2003–2007. Novus Biologicals’ CEO Karen Padgett credits the employees and quality products with the company's 151% percent revenue growth from 2003–2007.

Autophagy Antibody Sample Pack now available from Novus Biologicals

Release Date: 
Thursday, October 23, 2008 - 06:00

Novus is a world leader in supplying the highest quality antibodies for Autophagy research. The autophagy antibody sample packs represent a novel tool for researchers studying autophagy to investigate a broad variety of proteins involved in this emerging scientific area at a lost cost. Novus supplies over 300 antibodies, proteins and RNAi directly related to the field of autophagy research.

Phosphospecific Survivin Antibody [Ser20] now available from Novus Biologicals

Release Date: 
Wednesday, October 8, 2008 - 06:00

Survivin is a structurally unique inhibitor of apoptosis (IAP) that has been linked to protection from apoptosis, control of cell division, and cellular adaptation to stress. In order for survivin to provide this cytoprotection an interaction with at least one other IAP, such as XIAP, is necessary. It has recently been shown that Survivin is phosphorylated at Ser20 by protein kinase A (PKA) in the cytosol but not in the mitochondria.

The NOX4 antibody from Novus Biologicals now comes conjugated to Biotin, HRP, or HiLyte Fluor 488.

Release Date: 
Tuesday, October 7, 2008 - 06:00

Oxygen sensing is essential for homeostasis in all aerobic organisms. A phagocyte-type oxidase, similar to that responsible for the production of large amounts of reactive oxygen species (ROS) in neutrophil granulocytes, with resultant antimicrobial activity, has been postulated to function in the kidney as an oxygen sensor that regulates the synthesis of erythropoietin in the renal cortex.

SOX2 Antibodies

Release Date: 
Thursday, October 2, 2008 - 06:00

The Sox2 antibody, NB110-37235, has recently been tested in mouse and human samples for western blot and immunohistochemistry on paraffin sections.  See all Sox 2 antibodies.

TRPM1 Antibody and Iron-Moving Malfunction

Release Date: 
Wednesday, September 24, 2008 - 06:00

Defects in Mucolipin-1 are the cause of mucolipidosis type IV (MLIV), also known as sialolipidosis. MLIV is an autosomal recessive lysosomal storage disorder characterized by severe psychomotor retardation and ophthalmologic abnormalities, including corneal opacity, retinal degeneration and strabismus. Storage bodies of lipids and water-soluble substances are seen by electron microscopy in almost every cell type of the patients. Most patients are unable to speak or walk independently and reach a maximal developmental level of 1-2 years.

Pages